Product hopping in the drug industry — lessons from Albuterol

Wouters, Olivier J. ORCID: 0000-0002-2514-476X, Feldman, William B. and Tu, S. Sean (2022) Product hopping in the drug industry — lessons from Albuterol. New England Journal of Medicine, 387 (13). 1153 - 1156. ISSN 0028-4793

Text (Product Hopping in the Drug Industry — Lessons from Albuterol) - Accepted Version Available under License Creative Commons Attribution No Derivatives. Download (235kB)

• Author
• Scopus publication

Abstract

Product hops to albuterol inhalers containing hydrofluoroalkane rather than chlorofluorocarbons cost payers and patients billions of dollars. Without patent and regulatory reform, this pattern is likely to be repeated.

Item Type:	Article
Official URL:	https://www.nejm.org/
Additional Information:	© 2022 Massachusetts Medical Society.
Divisions:	Health Policy
Subjects:	R Medicine > RA Public aspects of medicine > RA0421 Public health. Hygiene. Preventive Medicine R Medicine > RM Therapeutics. Pharmacology
Date Deposited:	14 Oct 2022 09:09
Last Modified:	12 Dec 2024 03:20
URI:	http://eprints.lse.ac.uk/id/eprint/116986

Actions (login required)

View Item